208 related articles for article (PubMed ID: 29158373)
1. Revisiting Expectations in an Era of Precision Oncology.
Marchiano EJ; Birkeland AC; Swiecicki PL; Spector-Bagdady K; Shuman AG
Oncologist; 2018 Mar; 23(3):386-388. PubMed ID: 29158373
[TBL] [Abstract][Full Text] [Related]
2. Next-generation sequencing in precision oncology: Patient understanding and expectations.
Roberts JS; Gornick MC; Le LQ; Bartnik NJ; Zikmund-Fisher BJ; Chinnaiyan AM;
Cancer Med; 2019 Jan; 8(1):227-237. PubMed ID: 30600607
[TBL] [Abstract][Full Text] [Related]
3. [The origin of informed consent].
Mallardi V
Acta Otorhinolaryngol Ital; 2005 Oct; 25(5):312-27. PubMed ID: 16602332
[TBL] [Abstract][Full Text] [Related]
4. Molecular Tumor Boards: Ethical Issues in the New Era of Data Medicine.
Stoeklé HC; Mamzer-Bruneel MF; Frouart CH; Le Tourneau C; Laurent-Puig P; Vogt G; Hervé C
Sci Eng Ethics; 2018 Feb; 24(1):307-322. PubMed ID: 28281147
[TBL] [Abstract][Full Text] [Related]
5. [Medical consent in the era of personalized medicine: Issues and recommendations].
Glauzy A; Baertschi B; Duclos-Vallée JC
Med Sci (Paris); 2023; 39(8-9):658-663. PubMed ID: 37695156
[TBL] [Abstract][Full Text] [Related]
6. Dispositional optimism and therapeutic expectations in early-phase oncology trials.
Jansen LA; Mahadevan D; Appelbaum PS; Klein WM; Weinstein ND; Mori M; Daffé R; Sulmasy DP
Cancer; 2016 Apr; 122(8):1238-46. PubMed ID: 26882017
[TBL] [Abstract][Full Text] [Related]
7. Professionalism in global, personalized cancer care: restoring authenticity and integrity.
Surbone A
Am Soc Clin Oncol Educ Book; 2013; ():152-6. PubMed ID: 23714485
[TBL] [Abstract][Full Text] [Related]
8. A case of informed consent obtained from a patient with terminal cancer and his family using family function by the primary care physician.
Tsuboi K; Minegishi Y; Harada T; Ishizaki F; Nitta K
Hiroshima J Med Sci; 2007 Jun; 56(1-2):11-8. PubMed ID: 17760268
[TBL] [Abstract][Full Text] [Related]
9. Research participants' high expectations of benefit in early-phase oncology trials: are we asking the right question?
Weinfurt KP; Seils DM; Lin L; Sulmasy DP; Astrow AB; Hurwitz HI; Cohen RB; Meropol NJ
J Clin Oncol; 2012 Dec; 30(35):4396-400. PubMed ID: 23091107
[TBL] [Abstract][Full Text] [Related]
10. American Society of Clinical Oncology policy statement: oversight of clinical research.
American Society of Clinical Oncology
J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
[TBL] [Abstract][Full Text] [Related]
11. New clinical trial designs in the era of precision medicine: An overview of definitions, strengths, weaknesses, and current use in oncology.
Janiaud P; Serghiou S; Ioannidis JPA
Cancer Treat Rev; 2019 Feb; 73():20-30. PubMed ID: 30572165
[TBL] [Abstract][Full Text] [Related]
12. Quality of informed consent in cancer clinical trials: a cross-sectional survey.
Joffe S; Cook EF; Cleary PD; Clark JW; Weeks JC
Lancet; 2001 Nov; 358(9295):1772-7. PubMed ID: 11734235
[TBL] [Abstract][Full Text] [Related]
13. The changing face of clinical trials in the personalized medicine and immuno-oncology era: report from the international congress on clinical trials in Oncology & Hemato-Oncology (ICTO 2017).
Golan T; Milella M; Ackerstein A; Berger R
J Exp Clin Cancer Res; 2017 Dec; 36(1):192. PubMed ID: 29282151
[TBL] [Abstract][Full Text] [Related]
14. Information, communication, and cancer patients' trust in the physician: what challenges do we have to face in an era of precision cancer medicine?
Pichler T; Rohrmoser A; Letsch A; Westphalen CB; Keilholz U; Heinemann V; Lamping M; Jost PJ; Riedmann K; Herschbach P; Goerling U
Support Care Cancer; 2021 Apr; 29(4):2171-2178. PubMed ID: 32885314
[TBL] [Abstract][Full Text] [Related]
15. National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network.
Abrams J; Conley B; Mooney M; Zwiebel J; Chen A; Welch JJ; Takebe N; Malik S; McShane L; Korn E; Williams M; Staudt L; Doroshow J
Am Soc Clin Oncol Educ Book; 2014; ():71-6. PubMed ID: 24857062
[TBL] [Abstract][Full Text] [Related]
16. Complexity of Delivering Precision Medicine: Opportunities and Challenges.
Davis AA; McKee AE; Kibbe WA; Villaflor VM
Am Soc Clin Oncol Educ Book; 2018 May; 38():998-1007. PubMed ID: 30231318
[TBL] [Abstract][Full Text] [Related]
17. Ethical considerations of neuro-oncology trial design in the era of precision medicine.
Gupta S; Smith TR; Broekman ML
J Neurooncol; 2017 Aug; 134(1):1-7. PubMed ID: 28555425
[TBL] [Abstract][Full Text] [Related]
18. [Evaluation of consequences of written informed consent on physician-patient relations. Apropos of Huriet's law].
Gérard JP; Romestaing P; Marquis I; Wagner JP; Maillot MH; Buatois F; Bohas C
Bull Cancer; 1993 Oct; 80(10):903-4. PubMed ID: 8204933
[No Abstract] [Full Text] [Related]
19. Strategies For Clinical Implementation: Precision Oncology At Three Distinct Institutions.
Nadauld LD; Ford JM; Pritchard D; Brown T
Health Aff (Millwood); 2018 May; 37(5):751-756. PubMed ID: 29733728
[TBL] [Abstract][Full Text] [Related]
20. [Informed consent in oncology].
Hoerni B
Bull Cancer; 1989; 76(10):1055-61. PubMed ID: 2635633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
